Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired hemophilia

P Bouvry1, P Recloux

  • 1Centre Inter Universitaire Ambroise Paré, Department of Medicine, Mons, Belgium.

Haematologica
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Acquired hemophilia, an autoimmune disorder targeting factor VIII, presents challenges due to unpredictable treatment responses. Management involves controlling bleeding and reducing autoantibodies using various therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancer.

International journal of oncology·2011
Same author

A phase-ii study testing a combination chemotherapy with epirubicin and vindesine as 2nd line treatment for patients with advanced non-small-cell lung-cancer.

International journal of oncology·2011
Same author

A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same author

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy.

Lung cancer (Amsterdam, Netherlands)·2002
Same author

A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party.

Annals of oncology : official journal of the European Society for Medical Oncology·1999
Same author

Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party.

Lung cancer (Amsterdam, Netherlands)·1999
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

Area of Science:

  • Hematology
  • Immunology
  • Autoimmune Diseases

Background:

  • Acquired hemophilia is a rare autoimmune disorder characterized by autoantibodies against factor VIII.
  • It mimics hemophilia A clinically but arises from auto-immunity, not genetic mutation.
  • Associated conditions include autoimmune diseases, cancer, pregnancy, and drug use, though often idiopathic.

Purpose of the Study:

  • To outline the complex diagnostic and therapeutic landscape of acquired hemophilia.
  • To discuss strategies for managing acute hemorrhages in patients with factor VIII inhibitors.
  • To highlight the importance of individualized treatment selection based on clinical factors.

Main Methods:

  • Review of existing literature on acquired hemophilia.
  • Analysis of clinical presentations and associated conditions.

Related Experiment Videos

  • Synthesis of current therapeutic approaches for bleeding and inhibitor management.

    • Main Results:

    • Acquired hemophilia involves IgG autoantibodies against factor VIII, leading to bleeding.
    • Treatment is complex due to unpredictable responses to therapies.
    • Effective management requires addressing both acute bleeding and the underlying inhibitor.

    Conclusions:

    • Acquired hemophilia necessitates a multifaceted treatment approach.
    • Therapeutic decisions must consider autoantibody titer, treatment history, and bleeding severity.
    • Combined therapeutic strategies are often required for optimal outcomes.